Prosecution Insights
Last updated: November 04, 2026
Application No. 18/552,432

Use of the Sesquiterpene Lactone Tomentosin in the Treatment of Tumors Caused by Lymphoid Cell Lines

Non-Final OA §101§102§112
Filed
Sep 25, 2023
Priority
Mar 25, 2021 — IT 102021000007220 +2 more
Examiner
CHEN, PO-CHIH
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Universita Degli Studi Di Sassari
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
576 granted / 775 resolved
+14.3% vs TC avg
Moderate +15% lift
Without
With
+14.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
57 currently pending
Career history
829
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
33.2%
-6.8% vs TC avg
§102
19.0%
-21.0% vs TC avg
§112
30.8%
-9.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 775 resolved cases

Office Action

§101 §102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAIL ACTION This office action is a response to a 371 application filed -----9/25/2023, which is a national stage application of PCT/IB22/52375 filed 3/16/2022, which claims foreign priority to IT102021000007220 filed 3/25/2021. As filed, claims 1-7 are pending, wherein claims 1 and 2 are independent claims. Information Disclosure Statement The information disclosure statement (IDS) submitted on 9/25/2023 has been considered by the Examiner. Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Drawings The drawings of Figs .1 and 2 are objected to because the numbering are blurry and illegible. In addition, the word, “Figura”, in the abovementioned drawings is in Italian, and needs to translate into English. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-7 are rejected under 35 U.S.C. 101, because the claimed invention is directed to a judicial exception (i.e., a law of nature, a natural phenomenon, or an abstract idea) without significantly more. Claims 1-7 recite sesquiterpene lactone Tomentosin, or pharmaceutical composition thereof that represented a composition of matter, which represents a statutory category of invention. Next, the claim is evaluated to determine whether it is drawn to a judicial exception. The instantly claimed sesquiterpene lactone Tomentosin is one of naturally occurring compounds found in Mediterranean perennial shrub, such as Inula Viscosa (see non-patent literatures titled “Anticancer and Anti-Inflammatory Effect of Tomentosin: Cellular and Molecular Mechanisms”, hereinafter Omari, and titled “Inula Viscosa Extract Inhibits Growth of Colorectal Cancer Cells in vitro and in vivo Through Induction of Apoptosis”, hereinafter Bar-Shalom). In this case, the chemical structure making up the sesquiterpene lactone Tomentosin is compared to its naturally occurring counterpart found in plant source, and no evidence is presented that the process of extraction alters the structure or function of sesquiterpene lactone Tomentosin. The courts have emphasized that to show a marked difference, a characteristic must be changed as compared to nature, and cannot be an inherent or innate characteristic of the naturally occurring counterpart or an incidental change in a characteristic of the naturally occurring counterpart. Myriad, 133 S. Ct. at 2111, 106 USPQ2d at 1974-75. Thus, in order to be markedly different, Applicant must have caused the claimed product to possess at least one characteristic that is different from that of the counterpart. If there is no or only incidental change in any characteristic, the claimed product lacks markedly different characteristics and is a product of nature exception. The chemical structure of the instantly claimed sesquiterpene lactone Tomentosin is exactly the same as the counterparts found in the plant source but merely removed or relocated from the plant itself. Absent contrary evidence, the chemical structure of sesquiterpene lactone Tomentosin, regardless the origin, would retained the same properties. Because the instantly claimed sesquiterpene lactone Tomentosin does not exhibit markedly different characteristics when its characteristic are compared to the same compound found naturally, the compound of sesquiterpene lactone Tomentosin is drawn to a judicial exception, i.e., a nature-based product. No additional elements are presented that rely on, use, or apply the judicial exception, because the instantly claimed compound of sesquiterpene lactone Tomentosin contains the judicial exception. Next, the claim as a whole is analyzed to determine whether any additional element, or combination of elements, is sufficient to ensure the claim amounts to significantly more than the judicial exception. In claims 1-5, there are no elements in addition to the compound itself in a pharmaceutically acceptable form. The form of the composition does not serve to remove the claims from the judicial exception, because it does not amount to significantly more than the compound itself. As for claims 6 and 7, there are other elements (e.g. excipients, additives, another known active ingredient, etc.) in addition to the compound itself in a pharmaceutically acceptable form. The other elements of the composition do not remove the claims from the judicial exception, because they do not amount to significantly more than the plant extract containing the compound itself. Extracting sesquiterpene lactone Tomentosin for therapeutic or pharmaceutic use is also well understood, routine, and conventional as evidenced by Omari and Bar-Shalom, which teaches identical compound of sesquiterpene lactone Tomentosin or pharmaceutical composition thereof (e.g. Inula Viscosa or water extract thereof). Thus, claims 1-7 are drawn to a judicial exception without significantly more transforming it into patent eligible subject matter. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-7 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 1, the claim recites the phrase, “The sesquiterpene lactone Tomentosin” wherein the word, “the”, requires antecedent basis, and it is unclear where applicant has defined “a” sesquiterpene lactone Tomentosin. Without antecedent basis, the claim is rendered indefinite. Regarding claim 1, the claim recites the phrase, “the treatment” wherein the word, “the”, requires antecedent basis, and it is unclear where applicant has defined “a” treatment. Without antecedent basis, the claim is rendered indefinite. Regarding claim 2, the claim recites the phrase, “the active ingredient” wherein the word, “the”, requires antecedent basis, and it is unclear where applicant has defined “an” active ingredient. Without antecedent basis, the claim is rendered indefinite. Regarding claim 2, the claim recites the phrase, “the treatment” wherein the word, “the”, requires antecedent basis, and it is unclear where applicant has defined “a” treatment. Without antecedent basis, the claim is rendered indefinite. Regarding claim 4, the claim recites the phrase, “the patient’s needs” wherein the word, “the”, requires antecedent basis, and it is unclear where applicant has defined “a” patient’s needs. Without antecedent basis, the claim is rendered indefinite. Regarding claim 5, the claim recites the phrase, “the patient’s needs” wherein the word, “the”, requires antecedent basis, and it is unclear where applicant has defined “a” patient’s needs. Without antecedent basis, the claim is rendered indefinite. Regarding claim 6, the claim recites the phrase, “the patient’s needs” wherein the word, “the”, requires antecedent basis, and it is unclear where applicant has defined “a” patient’s needs. Without antecedent basis, the claim is rendered indefinite. Regarding claim 6, the claim recites the phrase, “sweeteners, flavorings and so on”. It is unclear what additional components pertains to the phrase “so on” and thus, the metes and bounds of “so on” is unclear, which rendered the claim indefinite. Regarding claim 6, the claim recites the phrase, “the common practice” wherein the word, “the”, requires antecedent basis, and it is unclear where applicant has defined “a” common practice. Without antecedent basis, the claim is rendered indefinite. Regarding claim 6, the claim recites the phrase, “the pharmaceutical formulative technique” wherein the word, “the”, requires antecedent basis, and it is unclear where applicant has defined “a” pharmaceutical formulative technique. Without antecedent basis, the claim is rendered indefinite. Regarding claim 6, the claim recites the phrase, “the known art” wherein the word, “the”, requires antecedent basis, and it is unclear where applicant has defined “a” known art. Without antecedent basis, the claim is rendered indefinite. Regarding claims 3-7, these claims are directly or indirectly dependent of claim 2, and they failed to correct the indefiniteness issue of claim 2, which rendered these claims indefinite. Claim Interpretation With regards to the intended use statements: “for use in the treatment of lymphoproliferative diseases, hematic tumors, myelomas, lymphomas, caused by lymphoid tumor cell lines” in claims 1-7; “as to allow the realization of pharmaceutical forms suitable for a total daily administration of 2-60 mg/kg of body weight of the active ingredient”, in claim 3; “in which said daily administration occurs in a single administration, or is divided into plural administration, depending on the patient’s needs” in claim 4 (this further limiting the abovementioned intended use statement in claim 3); “formulated in such a way that it can be administered orally and/or by injection, depending on the patient’s needs” in claim 5; and “usable in the treatment of lymphoproliferative diseases, hematic tumors, myelomas, lymphomas, caused by lymphoid tumor cell lines” in claim 7, they have not been accorded patentable weight for prior art purpose because such statement fails to limit the structure of the instant sesquiterpene lactone Tomentosin or failed to limit the components of the instant pharmaceutical composition. The Examiner finds that any prior art compound having the same structure or prior art composition having the same component would be capable of performing the intended use, according to the guidance in MPEP 2111.02(II). Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-7 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by “Inula Viscosa Extract Inhibits Growth of Colorectal Cancer Cells in vitro and in vivo Through Induction of Apoptosis”, hereinafter Bar-Shalom. Regarding claims 1-7, Bar-Shalom, for instance, teaches an Inula Viscosa (IV) leave or water extract thereof (i.e. both are pharmaceutical compositions, wherein water is a known excipient), which are known to contain Tomentosin and Inuvisocolide (i.e. another active ingredient), etc., and has shown to inhibit cell proliferation and induced apoptosis in vivo, when administered in an IP injection at 150 or 300 mg/kg. All of which meet all the limitations of these claims. PNG media_image1.png 416 486 media_image1.png Greyscale (pg. 1, first paragraph) PNG media_image2.png 306 324 media_image2.png Greyscale (pg. 4, left column, 2nd paragraph) PNG media_image3.png 124 322 media_image3.png Greyscale (pg. 8, left column, 2nd paragraph) Claims 1, 2, 5, and 6 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Chemical Abstract Registry No. 33649-15-9, hereinafter CAS159. Regarding claims 1, 2, 5, and 6, CAS159 teaches Tomentosin or pharmaceutical composition (with unbuffered water), which meet all the limitations of these claims. PNG media_image4.png 126 282 media_image4.png Greyscale PNG media_image5.png 32 632 media_image5.png Greyscale Claim Objections Claim 3 is objected to because of the following informalities: Regarding claim 3, the claim recites the phrase, “is comprised in such amounts as to allow the realization of pharmaceutical forms suitable for a total daily administration of 2-60 mg/kg of body weight of the active ingredient”, which contains typographical errors. The typographical errors can be corrected by reciting -- is comprised in --. Appropriate correction is required. Conclusion Claims 1-7 are rejected. Claim 3 is objected. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to PO-CHIH CHEN whose telephone number is (571)270-7243. The examiner can normally be reached Monday - Friday 10:00 am to 6:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached at (571)270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PO-CHIH CHEN/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Sep 25, 2023
Application Filed
Apr 23, 2026
Non-Final Rejection mailed — §101, §102, §112
Aug 24, 2026
Response after Non-Final Action
Aug 24, 2026
Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780809
8-(PICOLINAMIDE) SUBSTITUTED COUMARIN COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF
3y 2m to grant Granted Nov 03, 2026
Patent 12729209
MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT
3y 5m to grant Granted Sep 08, 2026
Patent 12715852
PREPARATION OF OPTICALLY ACTIVE ENANTIOMERS OF PIPERONYL AMINES BY RESOLUTION OF THE DIASTEREOMERIC SALTS
3y 11m to grant Granted Aug 25, 2026
Patent 12714693
USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS
1y 8m to grant Granted Aug 25, 2026
Patent 12703676
SYSTEMS AND METHODS FOR PRODUCING NITRILES
2y 2m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
89%
With Interview (+14.7%)
2y 5m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 775 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month